Chinese biotech valuations likely hit as trailblazer's Hong Kong shares sink

Biotech startups can expect more measured valuations should they list in Hong Kong, investors and bankers said, after shares of the first such firm to take advantage of rules allowing listings from pre-profit biotechs dropped 44 percent in the first month.